Ganitumab: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | |||
Revision as of 18:18, 10 February 2025
Ganitumab is a type of monoclonal antibody that is being studied in the treatment of certain types of cancer. It is a type of targeted therapy. Also called AMG 479.
Mechanism of Action
Ganitumab works by binding to the Insulin-like growth factor 1 receptor (IGF1R), which is found on the surface of many types of cancer cells. This binding blocks the action of the IGF1R, which is involved in cell growth and survival. By blocking the action of the IGF1R, ganitumab may slow the growth of cancer cells or cause them to die.
Clinical Trials
Ganitumab has been studied in clinical trials for the treatment of various types of cancer, including pancreatic cancer, Ewing's sarcoma, and ovarian cancer. Results from these trials have shown that ganitumab may have potential as a treatment for these and other types of cancer.
Side Effects
Like all chemotherapy drugs, ganitumab can cause side effects. These can vary from person to person and may include nausea, vomiting, diarrhea, and fatigue. It is important for patients to discuss any side effects they experience with their healthcare provider.
